These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 12630768)

  • 1. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.
    Saad ED; Machado MC; Wajsbrot D; Abramoff R; Hoff PM; Tabacof J; Katz A; Simon SD; Gansl RC
    Int J Gastrointest Cancer; 2002; 32(1):35-41. PubMed ID: 12630768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
    An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
    Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma.
    Ali CW; Kaye TF; Adamson DJ; Tait IS; Polignano FM; Highley MS
    J Gastrointest Cancer; 2007; 38(2-4):108-14. PubMed ID: 19089662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.
    Ishii H; Furuse J; Boku N; Okusaka T; Ikeda M; Ohkawa S; Fukutomi A; Hamamoto Y; Nakamura K; Fukuda H;
    Jpn J Clin Oncol; 2010 Jun; 40(6):573-9. PubMed ID: 20185458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.
    Hess V; Glimelius B; Grawe P; Dietrich D; Bodoky G; Ruhstaller T; Bajetta E; Saletti P; Figer A; Scheithauer W; Herrmann R
    Lancet Oncol; 2008 Feb; 9(2):132-8. PubMed ID: 18249033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
    Bauer TM; El-Rayes BF; Li X; Hammad N; Philip PA; Shields AF; Zalupski MM; Bekaii-Saab T
    Cancer; 2013 Jan; 119(2):285-92. PubMed ID: 22786786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
    Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer.
    Halm U; Schumann T; Schiefke I; Witzigmann H; Mössner J; Keim V
    Br J Cancer; 2000 Mar; 82(5):1013-6. PubMed ID: 10737382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
    Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
    Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
    Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
    Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine.
    Ziske C; Schlie C; Gorschlüter M; Glasmacher A; Mey U; Strehl J; Sauerbruch T; Schmidt-Wolf IG
    Br J Cancer; 2003 Oct; 89(8):1413-7. PubMed ID: 14562009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.
    Wasan HS; Springett GM; Chodkiewicz C; Wong R; Maurel J; Barone C; Rosbrook B; Ricart AD; Kim S; Spano JP
    Br J Cancer; 2009 Oct; 101(7):1162-7. PubMed ID: 19724276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine chemotherapy: clinical characteristics of long-term survivors].
    An SG; Kim DU; Song GA; Jang AL
    Korean J Gastroenterol; 2014 Dec; 64(6):356-63. PubMed ID: 25530587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma.
    Diaz CL; Cinar P; Hwang J; Ko AH; Tempero MA
    Am J Clin Oncol; 2019 Dec; 42(12):898-902. PubMed ID: 31634155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival.
    Takahashi H; Ohigashi H; Ishikawa O; Eguchi H; Gotoh K; Yamada T; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K; Yano M
    Ann Surg; 2010 Mar; 251(3):461-9. PubMed ID: 20134315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.
    Altwegg R; Ychou M; Guillaumon V; Thezenas S; Senesse P; Flori N; Mazard T; Caillo L; Faure S; Samalin E; Assenat E
    World J Gastroenterol; 2012 Mar; 18(12):1357-64. PubMed ID: 22493549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
    Lee JL; Kim SC; Kim JH; Lee SS; Kim TW; Park DH; Seo DW; Lee SK; Kim MH; Kim JH; Park JH; Shin SH; Han DJ
    Surgery; 2012 Nov; 152(5):851-62. PubMed ID: 22682078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival and prognostic factors of unresectable pancreatic cancer.
    Park JK; Yoon YB; Kim YT; Ryu JK; Yoon WJ; Lee SH
    J Clin Gastroenterol; 2008 Jan; 42(1):86-91. PubMed ID: 18097296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer.
    Saad ED; Reis PT; Borghesi G; Machado MC; Simon SD; Tabacof J; Gansl RC
    Rev Assoc Med Bras (1992); 2010; 56(1):22-6. PubMed ID: 20339781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer.
    Nakai Y; Kawabe T; Isayama H; Sasaki T; Yagioka H; Yashima Y; Kogure H; Arizumi T; Togawa O; Ito Y; Matsubara S; Hirano K; Sasahira N; Tsujino T; Tada M; Omata M
    Oncology; 2008; 75(1-2):120-6. PubMed ID: 18784438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.